4
Changes in Ownership
Axsome Therapeutics, Inc. Filed Acc 0001193125-25-206494
Chief Operating Officer sold 45,783 shares at an average $114.48 ($5,241,127)
- Chief Operating Officer acquired 40,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. Chief Operating Officer | 2025-09-16 | Sale 10b5-1 | −5,783 | $116.19 | $671,927 | 0 | D: show line 1 in the form |
| Jacobson Mark L. Chief Operating Officer | 2025-09-16 | Option exercise 10b5-1 | +25,000 | $4.95 | $123,750 | 25,000 | D: show line 2 in the form |
| Jacobson Mark L. Chief Operating Officer | 2025-09-16 | Option exercise 10b5-1 | +15,000 | $4.85 | $72,750 | 40,000 | D: show line 3 in the form |
| Jacobson Mark L. Chief Operating Officer | 2025-09-16 | Sale 10b5-1 | −40,000 | $114.23 | $4,569,200 | 0 | D: show line 4 in the form |
| Open-market sales · 45,783 sh · avg $114.48 · $5,241,127 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Jacobson Mark L. Chief Operating Officer | 2025-09-16 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −25,000 | 0 | D: show line 5 in the form | |||||
| Jacobson Mark L. Chief Operating Officer | 2025-09-16 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,000 | 0 | D: show line 6 in the form |
Loading xslF345X05/ownership.xml…